Efficacy of an antagonistic Anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human Non-Hodgkin's lymphoma and Hodgkin's disease.

被引：1
|
作者：
Long, Li
Patawaran, Montesa
Tong, Xia
Kantak, Seema
Aukerman, Sharon L.
Pryer, Nancy
Luqman, Mohammad
机构：
[1] Novartis Inst Biomed Res, Emeryville, CA USA
[2] LLC, XOMA US, Berkeley, CA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页码：72A / 72A
页数：1
相关论文
共 50 条
  • [21] The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's disease cells through multiple mechanisms.
    Law, CL
    McEarchern, JA
    Cerveny, CG
    Smith, LM
    Nesterova, A
    Gordon, KA
    Grewal, IS
    Wahl, AF
    BLOOD, 2005, 106 (11) : 425A - 426A
  • [22] Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin's lymphoma
    Daniel, Dylan L.
    Yang, Becky
    Totpal, Klara
    Wagner, Klaus
    Yee, Sharon
    Ross, Sarajane
    Ashkenazi, Avi
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3442S - 3442S
  • [23] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma (vol 10, pg 108, 1998)
    White, CA
    MINERVA BIOTECNOLOGICA, 1999, 11 (02) : 160 - 160
  • [24] Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
    O'Donnell, Robert T.
    Pearson, David
    McKnight, Hayes C.
    Ma, Ya Peng
    Tuscano, Joseph M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) : 1715 - 1722
  • [25] Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
    Robert T. O’Donnell
    David Pearson
    Hayes C. McKnight
    Ya Peng Ma
    Joseph M. Tuscano
    Cancer Immunology, Immunotherapy, 2009, 58 : 1715 - 1722
  • [26] Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
    Fanale, Michelle
    Assouline, Sarit
    Kuruvilla, John
    Solal-Celigny, Philippe
    Heo, Dae S.
    Verhoef, Gregor
    Corradini, Paolo
    Abramson, Jeremy S.
    Offner, Fritz
    Engert, Andreas
    Dyer, Martin J. S.
    Carreon, Daniel
    Ewald, Brett
    Baeck, Johan
    Younes, Anas
    Freedman, Arnold S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (02) : 258 - 265
  • [27] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [28] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [29] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Wagner, HN
    Wiseman, GA
    Marcus, CS
    Nabi, HA
    Nagle, CE
    Fink-Bennett, DM
    Lamonica, DM
    Conti, PS
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (02) : 267 - 272
  • [30] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Postema, EJ
    Oyen, WJG
    Boerman, OC
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 853 - 853
12345